Oragenics Reports Executive Changes & Compensation on Feb 12
Ticker: OGEN · Form: 8-K · Filed: Feb 12, 2024 · CIK: 1174940
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Oragenics just announced leadership changes and new executive pay, watch for strategic shifts.**
AI Summary
Oragenics, Inc. filed an 8-K on February 12, 2024, to report the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. This filing indicates changes in the company's leadership and executive compensation structure. For investors, this matters because changes in key personnel and their compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting the stock's value.
Why It Matters
Changes in executive leadership and compensation can significantly influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future company direction and stability, posing a medium risk to investors.
Analyst Insight
A smart investor would monitor subsequent company announcements for details on the new leadership's strategic plans and any changes in executive compensation that could impact future financial performance.
Key Players & Entities
- Oragenics, Inc. (company) — registrant filing the 8-K
- February 12, 2024 (date) — date of earliest event reported and filing date
- 001-32188 (null) — Commission File Number
- OGEN (null) — Trading Symbol for Common Stock
- NYSE American (null) — exchange where Common Stock is registered
FAQ
What was the specific date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 12, 2024.
What items were reported in this 8-K filing by Oragenics, Inc.?
Oragenics, Inc. reported on the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits' in this 8-K filing.
What is the trading symbol and exchange for Oragenics, Inc.'s Common Stock?
The trading symbol for Oragenics, Inc.'s Common Stock is OGEN, and it is registered on the NYSE American exchange.
What is the business address of Oragenics, Inc. as stated in the filing?
The business address of Oragenics, Inc. is 1990 Main Street, Suite 750, Sarasota, FL 34236.
What is the purpose of an 8-K filing for Oragenics, Inc. in this context?
An 8-K filing is used by Oragenics, Inc. to report significant events that shareholders should know about, such as changes in leadership and executive compensation, which occurred on February 12, 2024.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-02-12 16:45:18
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-005916.txt ( ) — 229KB
- ogen-20240212.xsd (EX-101.SCH) — 3KB
- ogen-20240212_lab.xml (EX-101.LAB) — 33KB
- ogen-20240212_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 12th day of February, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer